RxDoctor Payments DataLook up a doctor →

Sue Phelps

Nurse Practitioner · Athens, GANPI 1558093484

Payments from drug & device makers

$13,617in general payments, 2019–2025

Across 431 payments — averaging $31.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$5K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$684
  • Takeda Pharmaceuticals U.S.A., Inc.$586
  • Sanofi$552
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$1,1909%
  • Travel & lodging$2,88221%
  • Food & beverage$9,27168%
  • Education$2742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,617 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$53,903
Medicare patients
447
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide43$47,346
ClenpiqSod Picosulf/Mag Ox/Citric Ac64$11,087
Dexlansoprazole DrDexlansoprazole11$5,716
Famotidine347$4,913
Pantoprazole Sodium300$4,734
Colestipol Hcl70$3,689
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$2,252
Dicyclomine Hcl84$2,178
Omeprazole157$1,832
Sucralfate64$1,791
Colesevelam Hcl12$1,506
Esomeprazole Magnesium26$652
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl33$539
Lansoprazole16$463
Metronidazole12$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,929$47,34643 claims
Ferring Pharmaceuticals Inc.Clenpiq$57$11,08764 claims
SandozLansoprazole$38$46316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →